Trial · NCT06886347
Metastatic Nasopharyngeal Carcinoma
NCT06886347, Phase 1, Recruiting, Chen Xiaozhong
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Metastatic Nasopharyngeal Carcinoma. Trials, record NCT06886347. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06886347
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Metastatic Nasopharyngeal Carcinoma
- NCT number
- NCT06886347
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 47 participants, estimated
- Lead sponsor
- Chen Xiaozhong
- Conditions
- Metastatic Nasopharyngeal Carcinoma
- Interventions
- Penplimab Injection, Antitinib Hydrochloride Capsules, Gemcitabine
- First posted
- 2025-03-20
- Last updated
- 2025-03-20
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PFS | Baseline up to 2 years | PFS defined as the time from the first dose until the first documented progressive disease (PD) or death from any cause. |
| Secondary | Objective Response Rate（ORR） | Baseline up to 2 years | Percentage of subjects achieving complete response (CR) and partial response (PR) |
| Secondary | Disease Control Rate (DCR) | Baseline up to 2 years | Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD) |
| Secondary | Overall survival (OS) | Baseline up to 2 years | OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up |
| Secondary | Time to Response (TTR) | Baseline up to 2 years | TTR defined as the time from randomization to the first recorded CR or PR |
| Secondary | Duration of Response (DOR) | Baseline up to 2 years | DOR defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurred first. |
| Secondary | PD-L1 expression | Tumor tissue samples must be provided to the research center prior to initial administration | Evaluating the correlation between PD-L1 expression and efficacy in tumor tissue samples. |
| Secondary | Blood EBV level | Baseline up to 2 years | Evaluate the correlation between the copy number of EBV DNA in the blood of subjects and their efficacy. |
| Secondary | Evaluate the health-related quality of life (HRQoL) of subjects | Baseline up to 2 years | Evaluate the health-related quality of life (HRQoL) of subjects using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire scale。The minimum values is 1，the maximum values is 4，and whether higher scores mean a worse outcome. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06886347
GET https://conductscience.org/api/trials/v1/NCT06886347/registered